Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
From BioCentury This Week · · 30 min
This plays from the publisher's own server. We do not host a copy.
Description
Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals (https://www.biocentury.com/article/660996) for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit (https://www.biocentury.com/article/660972) against YolTech, why the GLOBE Medicare pricin (https://www.biocentury.com/article/661009)g model matters more for the precedent it sets than for its savings, and the Nobel Prize for optogenetics (https://www.biocentury.com/article/661031) as the first therapy based on the technology nears an FDA decision.
View full story: https://www.biocentury.com/article/661028
#ChinaBiotech #DrugPricing #IntellectualProperty #DrugDevelopment #NobelPrize
0:00 Introduction 1:30 China Pharma Deal Trends 11:29 Beam vs. YolTech Lawsuit 20:01 Small GLOBE, Big Precedent 24:05 Nobel Prize & Optogenetics
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)